<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Methylphenidate</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00422</strong>&#160; (APRD00657)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00422/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00422/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00422.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00422.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00422.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00422.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00422.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00422">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Methylphenidatum</td><td>Latin</td><td>INN</td></tr><tr><td>Metilfenidato</td><td>Italian</td><td>INN</td></tr><tr><td>MPH</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Methylphenidate Hydrochloride </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000117/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000117/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: JUMYIBMBTDDLNG-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 269.118256596</li>
              <li>Average Mass: 269.767</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000117">DBSALT000117</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Concerta</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Daytrana</td><td>Noven Therapeutics, LLC</td></tr><tr><td>Equasym XL</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Medikinet XL</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Metadate</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Methylin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Quillivant</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Quillivant XR</td><td>NextWave Pharmaceuticals </td></tr><tr><td>Riphenidate</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ritalin</td><td>Novartis</td></tr><tr><td>Rubifen SR</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/central-nervous-system-stimulants">Central Nervous System Stimulants</a></li>
<li><a href="/mesh/dopamine-uptake-inhibitors">Dopamine Uptake Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>113-45-1</td></tr><tr><th>Weight</th><td>Average: 233.3062<br>Monoisotopic: 233.141578857</td></tr><tr><th>Chemical Formula</th><td>C<sub>14</sub>H<sub>19</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>DUGOZIWVEXMGBE-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">methyl 2-phenyl-2-(piperidin-2-yl)acetate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC(=O)C(C1CCCCN1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00422.gif?1265922772">show</a>(7.79 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenylacetic Acid Derivatives</td></tr><tr><th>Direct parent</th><td>Phenylacetic Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Piperidines; Carboxylic Acid Esters; Ethers; Enolates; Dialkylamines; Polyamines</td></tr><tr><th>Substituents</th><td>piperidine; carboxylic acid ester; secondary amine; secondary aliphatic amine; enolate; polyamine; carboxylic acid derivative; ether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.</td></tr><tr><th>Pharmacodynamics</th><td>Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Methylphenidate also blocks the reuptake of norepinephrine and dopamine. Its mechanisms appear to be similar to those of dextroamphetamine.  Furthermore, it is a racemic mixture comprised of the d- and l-threo enantiomers. The d-threo enantiomer is more pharmacologically active than the l-threo enantiomer. </td></tr><tr><th>Mechanism of action</th><td>Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result.</td></tr><tr><th>Absorption</th><td>Readily absorbed in a biphasic manner when orally administered (tablets) to children diagnosed with ADHD and to healthy adults. In children and adults males, after administration of a single oral dose of Ritalin LA and Ritalin given in two doses 4 hours apart,  peak plasma concentration is reached approximately 2 hours for the first phase and 5-6 hours for the second phase. The absolute oral bioavailability of methylphenidate in children was 22&#177;8% for d-methylphenidate and 5&#177;3% for l-methylphenidate. These low values suggest that methylphenidate is highly metabolized presystemically. </td></tr><tr><th>Volume of distribution</th><td><p>d-methylphenidate = 2.65 L/kg;<br>
l-methylphenidate = 1.80 L/kg;</p></td></tr><tr><th>Protein binding</th><td>Binding to plasma proteins is low (10%-33%). </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Methylphenidate is hepatically metabolized. More specifically, it is rapidly and extensively metabolized by carboxylesterase CES1A1. Via this enzyme, methylphenidate undergoes de-esterification to ritalinic acid (a-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity.</p></td></tr><tr><th>Route of elimination</th><td>After oral administration of an immediate release formulation of methylphenidate, 78%-97% of the dose is excreted in the urine and 1%-3% in the feces in the form of metabolites within 48-96 hours. Only small quantities (</td></tr><tr><th>Half life</th><td>d-methylphenidate = 3-4 hours;
l-methylphenidate = 1-3 hours; 
Ritalinic acid = 3-4 hours; </td></tr><tr><th>Clearance</th><td><p>Systemic clearance for Ritalin LA and Ritalin tablets is as follows:<br>
d-methylphenidate=  0.40&#177;0.12 L/h/kg;<br>
l-methylphenidate = 0.73&#177;0.28 L/h/kg;</p></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD<sub>50</sub>=190mg/kg (orally in mice)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9941</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9663</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6564</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5466</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7964</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9601</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.532</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7897</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5985</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.592</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.897</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5245</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9265</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8539</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9328</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9648
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.5759
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7718 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8466
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7491
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Shire development inc</li>
<li>Ucb inc</li>
<li>Novartis pharmaceuticals corp</li>
<li>Mallinckrodt inc</li>
<li>Tris pharma inc</li>
<li>Ortho mcneil janssen pharmaceutical inc</li>
<li>Able laboratories inc</li>
<li>Actavis elizabeth llc</li>
<li>Watson laboratories inc</li>
<li>Ortho-McNeil-Janssen Pharmaceuticals, Inc.</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Alliant Pharmaceuticals Inc.</li>
<li>Alza Corp.</li>
<li><a href="http://www.apothecon.nl">Apothecon</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li><a href="http://www.chattem.com">Chattem Chemicals Inc.</a></li>
<li>D.M. Graham Laboratories Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.elan.com">Elan Pharmaceuticals Inc.</a></li>
<li><a href="http://www.eurand.com">Eurand Pharmaceuticals Inc.</a></li>
<li><a href="http://www.janssen-ortho.com">Janssen-Ortho Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li>McNeil Laboratories</li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.noven.com">Noven Pharmaceuticals Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho Mcneil Janssen Pharmaceutical Inc.</a></li>
<li><a href="http://www.patriotpharmaceuticals.com">Patriot Pharmaceuticals</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.purduepharma.com">Purdue Pharma LP</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li>Quality Care</li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li>Sciele Pharma Inc.</li>
<li><a href="http://www.shire.com">Shire Inc.</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li>Superior Pharmeceuticals</li>
<li><a href="http://www.ucb.com">UCB Pharma</a></li>
<li>Upstate Pharma LLC</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule, extended release</td><td>Oral</td><td></td></tr><tr><td>Patch</td><td>Transdermal</td><td>10 mg/9 hr; 15 mg/9 hr; 20 mg/9 hr; 30 mg/9 hr</td></tr><tr><td>Solution</td><td>Oral</td><td>5 mg/mL; 10mg/5mL</td></tr><tr><td>Suspension, extended release</td><td>Oral</td><td>25 mg/5 mL</td></tr><tr><td>Tablet</td><td>Oral</td><td>5 mg, 10 mg, 20 mg</td></tr><tr><td>Tablet, chewable</td><td>Oral</td><td>2.5 mg, 5 mg, 10 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine may decrease the effect of methylphendiate.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Methylphenidate increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>Methylphenidate may decrease the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Possible hypertensive crisis with this combination</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Possible hypertensive crisis with this combination</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Possible hypertensive crisis with this combination.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>Methylphenidate may antagonize the antihypertensive effect of Trandolapril. Monitor for changes in blood pressure if Methylphenidate is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Methylphenidate. Concomitant therapy is contraindicated.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid excessive quantities of coffee or tea (Caffeine).</li>
<li>Take on empty stomach: 1 hour before or 2 hours after meals.</li></ul></td></tr></tbody></table>